Sionna Therapeutics, Inc Common Stock
Price & Volume
Stats
See more52W Range | $7.25-$30.60 |
Market Cap | $768.9M |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$1.50 |
News
See moreYahoo Finance • 16 hours ago
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
Yahoo Finance • last month
Sionna Therapeutics to Participate in Upcoming September Investor Conferences
Yahoo Finance • last month
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
Yahoo Finance • 2 months ago
Guggenheim reiterates Buy rating on Sionna Therapeutics stock at $45 target
About
CEO | Mr. Michael Cloonan M.B.A. |
Address | 21 Hickory Drive, Waltham, MA, United States, 02451 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 41 |
